State Drug Alert: 141 Medicine Samples Fail CDSCO Quality Tests in March

Written By :  Susmita Roy
Published On 2026-04-24 12:30 GMT   |   Update On 2026-04-24 12:30 GMT
Advertisement

New Delhi: Reflecting persistent drug quality concerns in India's pharmaceutical market, the Central Drugs Standard Control Organisation (CDSCO) has flagged 141 drug samples as Not of Standard Quality (NSQ) in its March 2026 alert, based on test reports submitted by various State Drug Testing Laboratories across the country.

Reflecting persistent drug quality concerns in India’s pharmaceutical market, the Central Drugs Standard Control Organisation (CDSCO) has flagged a large number of drug samples as Not of Standard Quality (NSQ) in its March 2026 alert, based on test reports submitted by various State Drug Testing Laboratories across the country.

The alert covers a wide range of formulations, including tablets, capsules, syrups, injections, ointments, medical devices, and even cosmetic products, spanning therapeutic categories such as antibiotics, analgesics, antihypertensives, antidiabetics, gastrointestinal drugs, dermatological preparations, respiratory syrups, and hormonal therapies.

Several commonly used formulations have been flagged, including Prednisolone Tablets IP 10mg manufactured by Nestor Pharmaceuticals, Allopurinol Tablets IP 100mg manufactured by Zee Laboratories, Cefixime (Anhydrous) anufactured by Welcure Remedies,Aceclofeanc & Paracetamol Tablets manufactured by Titanes Pharm, Amoxycillin, Potassium Clavulanate & Lactic Acid Bacillus Tablets manufactured by Bionial Healthcare, Diclofenac Sodium, Telmisartan Tablets IP 40mg manufactured by Marc Lifesciences, Piperacillin & Tazobactam Inj I.P-4.5gm manufactured by Nitin Lifesciences, and others.

The list further includes popular formulations such as Paracetamol and Chlorzoxazone Tablets manufactured by Akums Drugs & Pharmaceuticals, Amoxycillin and Potassium Clavulanate Tablets IP manufactured by Sun Pharmaceuticals, PAN RFT Suspension manufactured by Alkem Laboratories.

Under the Drugs and Cosmetics Act, 1940, a drug is deemed “Not of Standard Quality” if it does not comply with the standards specified in the Indian Pharmacopoeia (IP) or other prescribed norms. Section 16(1)(a) defines these standards, making compliance mandatory for ensuring safety, efficacy, and quality.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News